However, as a preclinical study, the basic experimental results provided by this study confirmed the potential of [177Lu]Lu-PSMA-Q for prostate cancer treatment; this was sufficient to support clinical transformation and large-scale prospective studies to further validate its effectiveness, and to ensure that the effectiveness is not inferior to that of [177Lu]Lu-PSMA-617, while producing less radiation damage and toxic effects. This evidence concerns the gene FOLH1 and prostate carcinoma.